A recent retrospective study identifies key factors contributing to high failure rates of clinical trials evaluating treatments for head and neck squamous cell carcinoma.

Receiving a diagnosis of squamous cell carcinoma (SCC) can be an overwhelming experience, but it is important to remember ...

The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...

The trial was investigating whether the checkpoint inhibitor drug avelumab (Bavencio®) could be effective when added to the standard treatment of chemotherapy and radiation (chemoradiotherapy) for ...

Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.

For the last 20 years, the standard-of-care adjuvant treatment for resected pathologically defined high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) has been ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Panelists discuss how recurrent metastatic head and neck squamous cell carcinoma (HNSCC) manifests through symptoms such as persistent sore throat and neck lumps, with risk factors including tobacco ...

A new strategy that combines two types of PET scans can guide personalized radiotherapy for head and neck cancers, according ...

A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...